Are Vectura Group PLC, AstraZeneca plc And Lookers PLC ‘Screaming Buys’?

Should you add these 3 stocks to your portfolio? Vectura Group PLC (LON: VEC), AstraZeneca plc (LON: AZN) and Lookers PLC (LON: LOOK)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in pharmaceutical development company Vectura (LSE: VEC) have soared by around 10% today after it announced two pieces of very positive news flow. The first is that the FDA has approved the dual combination Utibron Neohaler and standalone monotherapy Seebri Neohaler products for treatment of chronic obstructive pulmonary disease (COPD). This has triggered a milestone payment of $22.5m from Novartis to Vectura as part of the deal agreed between the two companies regarding the treatment.

Hugely positive

Additionally, Vectura has also announced a €750k milestone payment from Novartis’s subsidiary Sandoz, relating to a development milestone for VR632, which is a generic, combined therapy for asthma/COPD.

Clearly, today’s news is hugely positive for Vectura, but despite its share price rise it still seems to offer excellent value for money. Certainly, its forward price to earnings (P/E) ratio of 95 may put a number of investors off, but with its bottom line forecast to rise by 141% next year, it puts Vectura on a price to earnings growth (PEG) ratio of only 0.3. This indicates that its shares appear to be well-worth buying for the long term.

Of course, the health care space offers other excellent opportunities. AstraZeneca (LSE: AZN) has endured a number of challenges in recent years, but now appears to have the right strategy with which to return to bottom line growth over the medium term.

Prudent buys

It has focused on engaging in M&A activity, with its strong balance sheet and excellent cash flow providing a great deal of opportunity in this space. Furthermore, the assets it has purchased seem to be very prudent buys, with its focus on treatments for global illnesses such as diabetes which are set to rapidly grow in prevalence in the coming years likely to offer a clear pathway to long term growth.

With AstraZeneca trading on a P/E ratio of just 15.3, it appears to offer excellent value for money. Certainly, its investors may need to be patient because profit growth may not return in the short run but, for investors taking a longer term view, now seems to be the perfect time to buy AstraZeneca — especially since its share price now appears to be exclusive of a bid premium.

Continued growth

Meanwhile, good news was also released today by car sales company Lookers (LSE: LOOK). Trading in its most recent quarter was in-line with expectations and it achieved record monthly performance in September. Crucially, integration of the 30 dealerships acquired through the purchase of Benfield Motor Group is progressing well, with them making a major contribution to the company’s financial performance.

Looking ahead, Lookers is forecast to increase its bottom line by 7% in the current year and by a further 10% next year. Despite this upbeat growth rate, its shares trade on a PEG ratio of only 1.1 and this indicates that they could be due for continued capital growth after posting a rise of 34% year-to-date. As such, now appears to be a good moment to buy a slice of Lookers.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£10 a day invested in UK shares could one day create a second income of over £3,000 a month!

Mark David Hartley outlines a strategy he’d use to aim for a second income that gets bigger over time, by…

Read more »

Investing Articles

£20,000 in savings? Here’s how I’d aim to turn that into passive income of £903 a month

Our writer shares one approach to passive income investing, spotlighting a quality FTSE 100 stock he recently added to his…

Read more »

Investing Articles

Great dividend stocks! Here’s the forecast for Associated British Food shares to 2027

Associated British Foods' shares have dropped in value this year. Does this present a dip-buying opportunity for dividend investors to…

Read more »

Investing Articles

Should I sell my FTSE All-Share index fund and buy a S&P 500 tracker instead?

Harvey Jones is wondering whether now is a good time to invest more money in the S&P 500, after a…

Read more »

Investing Articles

Should I buy dirt-cheap BT shares after the recent pullback?

BT shares were on the up but now they're sliding again after the board trimmed full-year guidance. Now Harvey Jones…

Read more »

Investing Articles

Up 28%, can the easyJet share price keep rising?

The easyJet share price has gained altitude over one year but plunged over five. Is now an attractive time for…

Read more »

British Isles on nautical map
Investing Articles

Should I buy more BAE Systems shares at 1,350p?

BAE Systems shares have had a fantastic run since early 2022, yet still don't appear overvalued. Is it now time…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

7% yield and a cheap valuation! Is this one of the best shares to buy this month?

Christopher Ruane has been looking for cheap shares to buy. This one has a 7% dividend yield, so is it…

Read more »